Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
US Judge Dismisses Gautam Adani Criminal Charges 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Chinese pharmaceutical giant WuXi AppTec (SS:603259) expects its first-half net profit to more than double, driven by soaring demand for its contract research and manufacturing services. The company announced on Thursday that net profit attributable for the six months ending June 30 is projected to jump 101.9% year-over-year, reaching 8.56 billion yuan (approximately $1.19 billion). This surge includes a significant one-time gain from the partial divestment of its subsidiary, WuXi XDC Cayman.
Excluding one-off items, adjusted net profit is forecast to rise 44.4% to 6.31 billion yuan, underscoring strong performance in its integrated CRDMO (Contract Research, Development, and Manufacturing Organization) business model. The firm said that increasing global demand for end-to-end drug development solutions has been a key growth driver.
Total revenue for the first half of 2025 is expected to grow 20.6% year-over-year, reaching approximately 20.8 billion yuan. Revenue from core operations alone rose by 24.2%, reflecting enhanced operational efficiency and expanded manufacturing capacity.
WuXi AppTec’s continued investment in innovation, infrastructure, and client-centric services is positioning the company as a global leader in pharmaceutical outsourcing. With the biotech and pharmaceutical sectors increasingly relying on external partners to accelerate drug development pipelines, WuXi AppTec appears well-placed to capitalize on this structural shift.
The company’s impressive growth trajectory reinforces confidence in its CRDMO strategy, which offers integrated solutions across research, development, and manufacturing phases. As global demand for efficient and scalable pharmaceutical services rises, WuXi AppTec’s performance signals strong momentum heading into the second half of the year.
